The hypothalamic–pituitary–adrenal axis was modulated by PS128 with decreased corticosterone concentration in serum and the expression of mineralocorticoid receptors in the amygdala. Oral administration of PS128 inhibited 5-HTPinduced VH during CRD. The ameliorative effect on VH suggests the potential application of PS128 for IBS. CLICK TO REVIEW
There is a bidirectional communication between the brain and the gut called “gutmicrobiota-brain axis (GMBA)” and its dysfunction causes numerous diseases. This review focuses on theinter-relationship between the gut microbiome and the Parkinson’s disease.(4) (PDF) Interrelationship between Gut microbiota and Parkinson’s disease. Available from: https://www.researchgate.net/publication/346456083_Interrelationship_between_Gut_microbiota_and_Parkinson’s_disease [accessed Jan 31 2021].
Interrelationship between Gut microbiota and Parkinson’s disease Read More »
We hypothesize that themicrobiota/metabolome enterotypes associated to non-TD subtypes may favor the developmentof gut inflammatory environment and gastrointestinal dysfunctions and therefore a more severeα-synucleinopathy. This study adds important information to PD pathogenesis and emphasizes thepotential pathophysiological link between gut microbiota/metabolites and PD motor subtypes(PDF) Clinical Phenotypes of Parkinson’s Disease Associate with Distinct Gut Microbiota and
Background: Parkinson’s disease (PD) is a multifactorial, chronic, and progressive neurodegenerative disease. α-Synuclein (α-syn), which is the main protein component of Lewy bodies, plays an important role in the pathological hallmarks of PD. However, the pathological function of α-syn and the molecular mechanisms responsible for the degeneration of dopaminergic neurons are still elusive. Summary: Cumulative evidence implicates that
We have reviewed the latest research on the role of gut microbiota in different nervous system diseases as well as FMT in the context of its application in neurological, psychiatric, and other nervous system-related diseases (Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, epilepsy, autism spectrum disorder, bipolar disorder, hepatic encephalopathy, neuropathic pain, etc.). CLICK TO REVIEW
Fecal Microbiota Transplantation: A New Therapeutic Attempt from the Gut to the Brain Read More »
Brain-derived neurotrophic factor, or BDNF, is a growth factor with broad relevance for aging, brain function, behavior, metabolism, energy expenditure, and satiety. BDNF serves as a cell signaling protein, plays key roles in numerous signaling pathways associated with a variety of disorders ranging from depression, schizophrenia, and addiction to obesity and diabetes, and may serve
Brain-derived neurotrophic factor (BDNF) Read More »
Abstract: Various benefits of probiotics to the host have been shown in numerous human clinical trials. These organisms have been proposed to act by improving the balance of the gut microbiota and enhancing the production of short-chain fatty acids, as well as by interacting with host cells in the gastrointestinal tract, including immune cells, nerve
ABSTRACT: Here, we give an overview of the progress that has been made over the past four decades in our understanding of this disorder. We review the role of mitochondria, environmental toxicants, alpha-synuclein and neuroinflammation in the development of PD. We also discuss more recent data from genetics, which strongly support the endosomal-lysosomal pathways and
Pathophysiology of Parkinson’s disease:
Mitochondria, alpha-synuclein and much more. . . Read More »
Pre-clinical and human clinical trial data reveal exciting potential for novel treatment targets and therapeutic modulation with prebiotics, medicinal herbs, probiotics, and synbiotics in health, aging, and neurodegeneration and are reviewed here. While greater insights and characterization of the microbiota-gut-brain axis have been revealed over the past decade, salient questions related to the pathology, pathogenesis